Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Autor: Stephan Windecker, Stefano Barco, Ulrike Held, Tim Sebastian, François Mach, Giuseppe Colucci, Marc Philip Righini, Nils Kucher, Thomas Rosemann, Roland Bingisser, Andre Frenk, Rebecca Spescha, Lucia Mazzolai, Stefan Stortecky, Bernhard Gerber

Publikováno v: Barco, Stefano; Bingisser, Roland; Colucci, Giuseppe; Frenk, André; Gerber, Bernhard; Held, Ulrike; Mach, Francois; Mazzolai, Lucia; Righini, Marc; Rosemann, Thomas; Sebastian, Tim; Spescha, Rebecca; Stortecky, Stefan; Windecker, Stephan; Kucher, Nils (2020). Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), p. 770. BioMed Central 10.1186/s13063-020-04678-4
Trials, vol. 21, no. 1, pp. 770
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Trials

Objectives The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad9a582d1159038210e15d6d804a5e7